Business Wire

Blade Therapeutics Initiates Additional Phase 1 Clinical Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis

Phase 1 clinical study to assess effect of cudetaxestat on pharmacokinetics of two approved therapies for idiopathic pulmonary fibrosis (IPF) Company on track to initiate planned phase 2 clinical ...
Business Wire

Blade Therapeutics Announces Positive Topline Data from Phase 1 Clinical Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Blade Therapeutics, Inc. (“Blade”), a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and ...
Healio

Angiotensin-converting enzyme inhibitor use before IPF diagnosis lowers mortality risk

Please provide your email address to receive an email when new articles are posted on . There was a significant independent link between angiotensin-converting enzyme inhibitor use and all-cause ...
EurekAlert!

Molecular mechanism uncovered: Beta-Carotene keeps enzymes active under heavy load

Enzymes are vital to metabolism and drive countless biological processes in humans, plants, and industry. Yet, when overwhelmed by excess substrate, some enzymes slow down — a phenomenon known as ...